The price of Beam Therapeutics Inc (NASDAQ: BEAM) closed at $45.07 in the last session, up 25.89% from day before closing price of $35.80. In other words, the price has increased by $+9.27 from its previous closing price. On the day, 7422830 shares were traded.
Ratios:
We take a closer look at BEAM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.72 and its Current Ratio is at 4.72. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.
Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 14 when FMR LLC sold 900,000 shares for $30.55 per share. The transaction valued at 27,496,912 led to the insider holds 1,235,511 shares of the business.
FMR LLC sold 1,565 shares of BEAM for $48,139 on Feb 13. The insider 1 now owns 2,771,913 shares after completing the transaction at $30.76 per share. On Jan 31, another insider, Evans John M., who serves as the CEO of the company, sold 60,000 shares for $25.33 each. As a result, the insider received 1,519,800 and left with 1,058,262 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 3.68B and an Enterprise Value of 2.66B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.72 while its Price-to-Book (P/B) ratio in mrq is 4.59. Its current Enterprise Value per Revenue stands at 32.60 whereas that against EBITDA is -7.00.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $41.07, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is 28.02, while the 200-Day Moving Average is calculated to be 27.57.
Shares Statistics:
According to the various share statistics, BEAM traded on average about 1.31M shares per day over the past 3-months and 1.6M shares per day over the past 10 days. A total of 71.28M shares are outstanding, with a floating share count of 67.81M. Insiders hold about 16.81% of the company’s shares, while institutions hold 77.22% stake in the company. Shares short for BEAM as of Jan 31, 2024 were 13.39M with a Short Ratio of 10.22, compared to 13.49M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 16.43% and a Short% of Float of 20.83%.
Earnings Estimates
The company has 12 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.01 for the current quarter, with a high estimate of $1.21 and a low estimate of -$1.46, while EPS last year was -$0.54. The consensus estimate for the next quarter is -$1.16, with high estimates of -$0.58 and low estimates of -$1.49.
Analysts are recommending an EPS of between -$2.28 and -$5.14 for the fiscal current year, implying an average EPS of -$4.42. EPS for the following year is -$4.6, with 14 analysts recommending between -$3.01 and -$6.21.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $18.67M. It ranges from a high estimate of $40M to a low estimate of $12M. As of the current estimate, Beam Therapeutics Inc’s year-ago sales were $20.04M, an estimated decrease of -6.80% from the year-ago figure.
A total of 13 analysts have provided revenue estimates for BEAM’s current fiscal year. The highest revenue estimate was $101.52M, while the lowest revenue estimate was $67M, resulting in an average revenue estimate of $79.2M. In the same quarter a year ago, actual revenue was $60.92M, up 30.00% from the average estimate.
